PTC THERAPEUTICS INC (PTCT)

US69366J2006 - Common Stock

27.07  +1.03 (+3.96%)

After market: 27.07 0 (0%)

Full profile views are only available for registered users, you can see which data is available below.

Examples of complete profiles are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional data.

PTC THERAPEUTICS INC

NASDAQ:PTCT (2/23/2024, 7:07:19 PM)

After market: 27.07 0 (0%)

27.07

+1.03 (+3.96%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
Chartmill FA Rating
Valuation
Growth
Profitability
Health
Dividend
Overview
Earnings (Last)
Earnings (Next)
Ins Owners
Inst Owners
Market Cap2.04B
Shares
PEN/A
Fwd PEN/A
Dividend YieldN/A
Analysts
IPO
Stock Screener Links
Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

PTCT Daily chart

Company Profile

PTC Therapeutics, Inc. is a biopharmaceutical company. The company is headquartered in South Plainfield, New Jersey and currently employs 1,402 full-time employees. The company went IPO on 2013-06-20. The firm is focused on the discovery, development and commercialization of clinically differentiated medicines that provide benefits to patients with rare disorders. Its portfolio pipeline includes several commercial products and product candidates in various stages of development, including clinical, pre-clinical and research and discovery stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology, metabolism and oncology. The firm has two products, Translarna (ataluren) and Emflaza (deflazacort), for the treatment of Duchenne muscular dystrophy (DMD). The company also offers Upstaza, a gene therapy for the treatment of Aromatic L-Amino Decarboxylase (AADC) deficiency, and Evrysdi, a treatment for spinal muscular atrophy (SMA). Its splicing platform includes PTC518, which is being developed for the treatment of Huntington’s disease (HD).

Company Info

PTC THERAPEUTICS INC

100 Corporate Ct

South Plainfield NEW JERSEY 07080

P: 19082227000

CEO: Stuart W. Peltz

Employees: 1402

Website: https://www.ptcbio.com/

PTCT News

News Image2 days ago - PTC Therapeutics, Inc.PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

/PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on Feb. 15, 2024, the company approved non-statutory stock options to purchase an...

News Image9 days ago - PTC Therapeutics, Inc.PTC Therapeutics to Host Conference Call to Discuss Fourth Quarter and Full Year 2023 Financial Results

/PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will host a webcast conference call to report its fourth quarter and...

News Image11 days ago - Market News VideoNotable Tuesday Option Activity: DIN, PTCT, TOL
News Image12 days ago - Seeking AlphaBiogen gets EU approval for Friedrich's ataxia drug (NASDAQ:BIIB)

Biogen (BIIB) said it has received EU approval for its drug Skyclarys for the treatment of Friedreich’s ataxia, or FA, in patients aged 16 years and older. Read more here.

News Image13 days ago - The Motley Fool1 of Sarepta Therapeutics' Competitors Just Got Hammered. Will It Help the Stock?

Bad news for one player does not always equal good news for another.

News Imagea month ago - Market News VideoNoteworthy Friday Option Activity: UTI, HUN, PTCT

PTCT Twits

Here you can normally see the latest stock twits on PTCT, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example